Schizophrenia: more dopamine, more D2 receptors.

  title={Schizophrenia: more dopamine, more D2 receptors.},
  author={Philip Seeman and Shitij Kapur},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  volume={97 14},
  • P. Seeman, S. Kapur
  • Published 5 July 2000
  • Psychology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
Schizophrenia is a major therapeutic challenge of modern medicine, and one of the last frontiers of brain research. The illness is defined by delusions, hallucinations, disorganized behavior, and cognitive difficulties such as memory loss. It occurs in ≈1% of the world population and usually first appears in early adulthood. Although antipsychotic medications have dramatically improved the lives of patients with schizophrenia, the causes of the illness remain unknown. Of the many contemporary… 

Figures from this paper

Dopamine Receptors and the Treatment of Schizophrenia

This chapter reviews the pharmacological effects of typical and atypical antipsychotics on the different dopamine receptor subtypes, as well as on non-dopaminergic receptor targets, and on the prominent role of D2 receptor blockade as the primary site of their action in brain.

Dopamine receptors in the brains of schizophrenia patients: a meta‐analysis of the findings

It is concluded that a subgroup of schizophrenia patients manifests increased DA D 2 receptor density and decreased receptor affinity, and in the absence of medication, these changes may become more pronounced with age.

Drug models of schizophrenia

Findings from dopaminergic, glutamatergic, serotonergic, cannabinoid, GABA, cholinergic and kappa opioid pharmacological drug models are reviewed to evaluate their similarity to schizophrenia.

Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia.

These findings are consistent with a selective reduction in DARPP-32 levels in schizophrenic subjects, and may play an important role in the pathophysiological changes in dopamine and glutamate function reported in patients with schizophrenia.

The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia

Psychosis pathways converge via D2High dopamine receptors

The evidence suggests that there are multiple pathways that convergetoelevate the D2High state in brain regions and that this elevation may elicit psychosis.

Understanding Neuropsychiatric Disorders: Structural imaging of schizophrenia

Emil Kraepelin, one of the founding fathers of the diagnostic concept of schizophrenia, argued that the disorder was underpinned by abnormalities in brain structure, and the vast majority of research aimed at investigating the neuroanatomical underpinnings of SZ has focused on GM.

Therapeutic Advances in Psychopharmacology

Findings from dopaminergic, glutamatergic, serotonergic, cannabinoid, GABA, cholinergic and kappa opioid pharmacological drug models are reviewed to evaluate their similarity to schizophrenia.



Quantification of Neuroreceptors in the Living Human Brain: IV. Effect of Aging and Elevations of D2-Like Receptors in Schizophrenia and Bipolar Illness

  • D. WongG. Pearlson A. Gjedde
  • Medicine, Psychology
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 1997
Increases in D2 dopamine receptor density were found in seven psychotic patients with bipolar affective illness compared with seven nonpsychotic patients and 24 control subjects as well as in 22 drug-naive schizophrenic patients compared with the24 control subjects.

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Elevated synaptic dopamine was predictive of good treatment response of positive symptoms to antipsychotic drugs and increased stimulation of D(2) receptors by dopamine in schizophrenia, consistent with increased phasic activity of dopaminergic neurons.

Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4.

  • P. Seeman
  • Psychology, Medicine
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • 1992
An analysis of the literature indicates that therapeutic concentrations of antipsychotic drugs act primarily at D2 receptors, with the exception of clozapine, which acts at D4 receptors.

D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.

The hypothesis of generally elevated central D2 dopamine receptor densities in schizophrenia was not supported by the present findings, and significantly higher densities were found in the left than in the right putamen but not in the caudate nucleus.

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

  • A. BreierT. Su D. Pickar
  • Biology, Psychology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1997
In the clinical study, patients with schizophrenia compared with healthy volunteers had significantly greater amphetamine-related reductions in [11C]raclopride specific binding, providing direct evidence for the hypothesis of elevated Amphetamine-induced synaptic dopamine concentrations in schizophrenia.

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.

The rapid release of clozapine and quetiapine from D2 receptors by endogenous dopamine may contribute to low D2 receptor occupancy and to early clinical relapse upon withdrawal of these medications.

Antipsychotic drug doses and neuroleptic/dopamine receptors

It is reported here that all clinically effective antipsychotic drugs (tested so far) block the stereo-specific binding of 3H-haloperidol at concentrations which correlate directly with the clinical potencies.

Brain receptors for antipsychotic drugs and dopamine: direct binding assays.

Various antipsychotic drugs inhibited this stereospecific component in both the dopamine and haloperidol assays, and these inhibitory potencies correlated with the clinical doses used for controlling schizophrenia.